{"title": "Impfungen bei Immunsuppression", "author": "PHC Primary; Hospital Care; Ekrem Temizel; Christopher M\u00fcssig; Bernhard Wingeier; Benedikt M Huber; Gisela Etter; Claudia Ruth Bollinger; Kathleen Jahn; Maja Weisser Rohacek; Felix Burkhalter Pirovino; Irene Abela; Philip Tarr", "url": "https://phc.swisshealthweb.ch/de/article/doi/phc-d.2023.10707", "hostname": "swisshealthweb.ch", "description": null, "sitename": "Ekrem Temizel,Christopher M\u00fcssig,Bernhard Wingeier,Benedikt M. Huber,Gisela Etter,Claudia Ruth Bollinger,Kathleen Jahn,Maja Weisser Rohacek,Felix Burkhalter Pirovino,Irene Abela,Philip Tarr", "date": "2023-09-06", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "1 Harpaz R, Dahl RM, Dooling KL. Prevalence of Immunosuppression Among US Adults, 2013. JAMA. 2016 Dec;316(23):2547\u20138.\n2 Bundesamt f\u00fcr Gesundheit, Eidgen\u00f6ssische Kommission f\u00fcr Impffragen. Schweizerischer Impfplan 2023: Richtlinien und Empfehlungen [Internet]. Bern: Bundesamt f\u00fcr Gesundheit; 2023 [cited 2023 Feb 8]. Available from:\n[https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/allgemeine-empfehlungen/schweizerischer-impfplan.pdf.download.pdf/schweizerischer-impfplan-de.pdf](https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/allgemeine-empfehlungen/schweizerischer-impfplan.pdf.download.pdf/schweizerischer-impfplan-de.pdf)\n.\n3 Horneff G. Biologic-associated infections in pediatric rheumatology. Curr Rheumatol Rep. 2015 Nov;17(11):66.\n4 Atzeni F, Batticciotto A, Masala IF, Talotta R, Benucci M, Sarzi-Puttini P. Infections and Biological Therapy in Patients with Rheumatic Diseases. Isr Med Assoc J. 2016;18(3-4):164\u20137.\n5 Bundesamt f\u00fcr Gesundheit und Eidgen\u00f6ssische Kommission f\u00fcr Impffragen. Impfprinzipien und Empfehlungen f\u00fcr Personen mit chronisch entz\u00fcndlichen Darmerkrankungen oder anderen gastroenterologischen (Auto-)Immunerkrankungen [Internet]. BAG-Bulletin. 2017 Dec 11 [cited 2022 Jan 15];50:28\u201331. Available from:\n[https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/empfehlungen-risikogruppen-risikosituationen/impfprinzipien-imid-gastro.pdf.download.pdf](https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/empfehlungen-risikogruppen-risikosituationen/impfprinzipien-imid-gastro.pdf.download.pdf)\n6 Bundesamt f\u00fcr Gesundheit und Eidgen\u00f6ssische Kommission f\u00fcr Impffragen. Empfehlung zur Impfung von Personen mit malignen Erkrankungen und deren Haushaltskontakte. BAG-Bulletin [Internet]. 2022 May 16 [cited 2023 Jan 9];20:20\u201330. Available from:\n[https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/empfehlungen-risikogruppen-risikosituationen/empfehlungen-onkologie.pdf.download.pdf/BU_20_22_Impfempfehlung_Onkologie_DE.pdf](https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/empfehlungen-risikogruppen-risikosituationen/empfehlungen-onkologie.pdf.download.pdf/BU_20_22_Impfempfehlung_Onkologie_DE.pdf)\n7 Wagner N, Assmus F, Arendt G, Baum E, Baumann U, Bogdan C, et al. Impfen bei Immundefizienz: Anwendungshinweise zu den von der St\u00e4ndigen Impfkommission empfohlenen Impfungen. (IV) Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entz\u00fcndlichen Erkrankungen und unter immunmodulatorischer Therapie. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019 Apr;62(4):494\u2013515.\n8 B\u00fchler S, Eperon G, Ribi C, Kyburz D, van Gompel F, Visser LG, et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly. 2015 Jul;145:w14159.\n10 Bundesamt f\u00fcr Gesundheit und Eidgen\u00f6ssische Kommission f\u00fcr Impffragen. Pneumokokkenimpfung: Empfehlungen zur Verhinderung von invasiven Pneumokokkenerkrankungen bei Risikogruppen. BAG-Bulletin [Internet]. 2014 Feb 17 [cited 2022 Jan 15];8:129\u2013141. Available from:\n[https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/empfehlungen-spezifische-erreger-krankheiten/pneumokokken/empfehlung-verhinderung-invasive-pneumokokkenerkrankung-risikogruppen.pdf.download.pdf/bu-8-2014-pneumokokken-risikogruppen.pdf](https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/empfehlungen-spezifische-erreger-krankheiten/pneumokokken/empfehlung-verhinderung-invasive-pneumokokkenerkrankung-risikogruppen.pdf.download.pdf/bu-8-2014-pneumokokken-risikogruppen.pdf)\n. Published online February 2014\n11 Schweizerische Gesellschaft f\u00fcr Rheumatologie. Impfempfehlungen f\u00fcr Patienten mit entz\u00fcndlich-rheumatischen Erkrankungen [Internet]. Z\u00fcrich: SGR; 2020 [cited 2022 Jan 15]. Available from:\n[https://www.rheuma-net.ch/de/dok/sgr-dokumente/behandlung/therapie/weitere/72-impfempfehlungen-fuer-patienten-mit-entzuendlich-rheumatischen-erkrankungen/file?force-download=1](https://www.rheuma-net.ch/de/dok/sgr-dokumente/behandlung/therapie/weitere/72-impfempfehlungen-fuer-patienten-mit-entzuendlich-rheumatischen-erkrankungen/file?force-download=1)\n12 Rheumaliga Schweiz [Internet]. Z\u00fcrich: Rheumalige Schweiz; c2023 [cited 2022 Jan 15]. \u00dcber Infektionen, Immunsuppression und Impfungen; [about 5 screens]. Available from:\n[https://www.rheumaliga.ch/blog/2020/infektionen-immunsuppression-impfungen](https://www.rheumaliga.ch/blog/2020/infektionen-immunsuppression-impfungen)\n13 pneumo.ch [Internet]. Basel: Schweizerische Gesellschaft f\u00fcr Pneumologie; c2023 [cited 2022 Jan 15]. Available from:\n[http://www.pneumo.ch/de/home.html](https://www.pneumo.ch/de/home.html)\n14 lungenliga.ch [Internet]. Bern: Lungenliga Schweiz; c2023 [cited 2022 Jan 15]. Available from:\n[https://www.lungenliga.ch/de/startseite.html](https://www.lungenliga.ch/de/startseite.html)\n15 Rieger C, Liss B, Mellinghoff S, Buchheidt D, Cornely OA, Egerer G, et al. Impfungen bei Tumorpatienten. Onkopedia [Internet]. 2019 Aug [cited 2023 Feb 7];[10 p]. Available from:\n[https://www.onkopedia.com/de/onkopedia/guidelines/impfungen-bei-tumorpatienten/@@guideline/html/index.html](https://www.onkopedia.com/de/onkopedia/guidelines/impfungen-bei-tumorpatienten/@@guideline/html/index.html)\n16 sgh-ssh.ch [Internet]. Z\u00fcrich: Schweizerische Gesellschaft f\u00fcr H\u00e4matologie; c2023 [cited 2023 Feb 15]. Available from:\n[https://www.sgh-ssh.ch](https://www.sgh-ssh.ch)\n17 sggssg.ch [Internet]. Bern: Schweizerische Gesellschaft f\u00fcr Gastroenterologie; c2020 [cited 2022 Jan 15]. Available from:\n[https://sggssg.ch](https://sggssg.ch)\n18 swissneuro.ch [Internet]. Basel: Schweizerische Neurologische Gesellschaft (SNG); c2022 [cited 2022 Mar 13]. Available from:\n[https://www.swissneuro.ch/Home](https://www.swissneuro.ch/Home)\n19 sginf.ch [Internet]. Bern: Schweizerische Gesellschaft f\u00fcr Infektiologie; c2019 [cited 2022 Jan 15]. Available from:\n[https://www.sginf.ch](https://www.sginf.ch)\n20 swissnoso.ch [Internet]. Bern: Nationales Zentrum f\u00fcr Infektionspr\u00e4vention; c2023 [cited 2022 Jan 15]. Available from:\n[https://www.swissnoso.ch](https://www.swissnoso.ch)\n21 Notter J, Ehrenzeller S, Tarr P. Im Auftrag des. Empfehlungen f\u00fcr Impfungen sowie zur Verh\u00fctung und zum Ausbruchsmanagement von \u00fcbertragbaren Krankheiten in den Asylzentren des Bundes und den Kollektivunterk\u00fcnften der Kantone: Handbuch f\u00fcr Gesundheitspersonal im Rahmen des Konzeptes zur Sicherstellung der Erkennung, Behandlung und Verh\u00fctung von \u00fcbertragbaren Krankheiten sowie des Zugangs zur notwendigen Gesundheitsversorgung [Internet]. Bern: Bundesamtes f\u00fcr Gesundheit (BAG); 2018 [cited 2022 Jan 15]. Available from:\n[https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-i/gesundheitsversorgung-asyl/empfehlungen-impfungen-ausbruchsmanagement-asyl.pdf.download.pdf/empfehlungen-impfungen-ausbruchsmanagement-asyl-de.pdf](https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-i/gesundheitsversorgung-asyl/empfehlungen-impfungen-ausbruchsmanagement-asyl.pdf.download.pdf/empfehlungen-impfungen-ausbruchsmanagement-asyl-de.pdf)\n. :79\n22 Bundesamt f\u00fcr Gesundheit und Eidgen\u00f6ssische Kommission f\u00fcr Impffragen . Empfehlungen zur Impfung von Empf\u00e4ngerinnen und Empf\u00e4ngern von Blut-Stammzellen. BAG-Bulletin [Internet]. 2012 Mar 21 [updated 2014; cited 2022 Jan 15];21:363\u2013370. Available from:\n[https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/empfehlungen-risikogruppen-risikosituationen/empfehlungen-impfung-blut-stammzellen.pdf.download.pdf/bu-08-blutstammzellen.pdf](https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/empfehlungen-risikogruppen-risikosituationen/empfehlungen-impfung-blut-stammzellen.pdf.download.pdf/bu-08-blutstammzellen.pdf)\n.\n23 Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al.; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014 Feb;58(3):e44\u2013100.\n24 Ehl S, Bogdan C, Niehues T, Burchard G, Baumann U, Hecht J, et al. Impfen bei Immundefizienz: Anwendungshinweise zu den von der St\u00e4ndigen Impfkommission empfohlenen Impfungen. (II) Impfen bei 1. Prim\u00e4ren Immundefekterkrankungen und 2. HIV-Infektion. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018 Aug;61(8):1034\u20131051. Erratum in: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018 Oct;61(10):1307\u20131308. Erratum in: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019 Mar;62(3):378.\n25 Solana R, Tarazona R, Gayoso I, Lesur O, Dupuis G, Fulop T. Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans. Semin Immunol. 2012 Oct;24(5):331\u201341.\n26 Heppner HJ, Leischker A, Wutzler P, Kwetkat A. Impfungen im h\u00f6heren Lebensalter. Internist (Berl). 2018 Feb;59(2):205\u201312.\n27 F\u00fcl\u00f6p T, Dupuis G, Witkowski JM, Larbi A. The Role of Immunosenescence in the Development of Age-Related Diseases. Rev Invest Clin. 2016;68(2):84\u201391.\n28 Castelo-Branco C, Soveral I. The immune system and aging: a review. Gynecol Endocrinol. 2014 Jan;30(1):16\u201322.\n29 Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and human vaccine immune responses. Immun Ageing. 2019 Sep;16(1):25.\n30 Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006 Feb;54(2):628\u201334.\n31 Wu J, Keeley A, Mallen C, Morgan AW, Pujades-Rodriguez M. Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England. CMAJ. 2019 Jun;191(25):E680\u20138.\n32 Prymula R, Siegrist CA, Chlibek R, Zemlickova H, Vackova M, Smetana J, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet. 2009 Oct 17;374(9698):1339\u201350.\n33 Brandts CH, Ndjav\u00e9 M, Graninger W, Kremsner PG. Effect of paracetamol on parasite clearance time in Plasmodium falciparum malaria. Lancet. 1997 Sep;350(9079):704\u20139.\n34 Etminan M, Sodhi M, Ganjizadeh-Zavareh S. Should Antipyretics Be Used to Relieve Acute Adverse Events Related to COVID-19 Vaccines? Chest. 2021 Jun;159(6):2171\u20132.\n35 Doed\u00e9e AM, Boland GJ, Pennings JL, de Klerk A, Berbers GA, van der Klis FR, et al. Effects of prophylactic and therapeutic paracetamol treatment during vaccination on hepatitis B antibody levels in adults: two open-label, randomized controlled trials. PLoS One. 2014 Jun;9(6):e98175.\n36 Jefferies S, Braithwaite I, Walker S, Weatherall M, Jennings L, Luck M, et al.; Pi Study Group. Randomized controlled trial of the effect of regular paracetamol on influenza infection. Respirology. 2016 Feb;21(2):370\u20137.\n37 Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011 Feb 16;2011(2):CD008794.\n38 Bundesamt f\u00fcr Gesundheit (BAG) [Internet]. Bern: BAG; c2019 [cited 2022 Jan 15]. Masern verursachen zwei Todesf\u00e4lle; [about 2 screens]. Available from:\n[https://www.bag.admin.ch/bag/de/home/das-bag/aktuell/news/masern-verursachen-zwei-todesfaelle.html](https://www.bag.admin.ch/bag/de/home/das-bag/aktuell/news/masern-verursachen-zwei-todesfaelle.html)\n.\n39 Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis. 2004 Nov;39(9):1300\u20136.\n40 Furer V, Rondaan C, Heijstek M, van Assen S, Bijl M, Agmon-Levin N, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019 Sep;5(2):e001041.\n41 Kr\u00f6ner PT, Picco MF, Cangemi JR, Hayney MS, Farraye FA, Caldera F. The Burden of Vaccine-preventable Diseases in Patients With Inflammatory Bowel Disease. J Clin Gastroenterol. 2022 Oct;56(9):798\u2013804.\n42 Bingham CO 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010 Jan;62(1):64\u201374.\n43 Winthrop KL, Bingham CO 3rd, Komocsar WJ, Bradley J, Issa M, Klar R, et al. Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy. Arthritis Res Ther. 2019 Apr;21(1):102.\n44 Bundesamt f\u00fcr Gesundheit, Eidgen\u00f6ssische Kommission f\u00fcr Impffragen. Schweizerischer Impfplan 2021 [Internet]. Bern: Bundesamt f\u00fcr Gesundheit; 2021 [cited 2022 Jan 15]. Available from:\n[https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/allgemeine-empfehlungen/schweizerischer-impfplan.pdf.download.pdf/schweizerischer-impfplan-de.pdf](https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/allgemeine-empfehlungen/schweizerischer-impfplan.pdf.download.pdf/schweizerischer-impfplan-de.pdf)\n45 Epstein, D.. Guidelines for vaccination of adult solid organ transplant candidates and recipients [Internet]. Stanford: Stanford Healthcare Vaccination Subcommittee; c2018 [cited 2023 Feb 7]. Available from: https://med.stanford.edu/content/dam/sm/bugsanddrugs/documents/clinicalpathways/SHC-Vaccination-SOT.pdf\n46 Bundesamt f\u00fcr Gesundheit und Eidgen\u00f6ssische Kommission f\u00fcr Impffragen . Impfprinzipien und Empfehlungen f\u00fcr Personen mit chronisch entz\u00fcndlichen Darmerkrankungen oder anderen gastroenterologischen (Auto-)Immunerkrankungen. BAG-Bulletin [Internet]. 2017 Dec 11 [cited 2022 Jan 15];50:28\u201331. Available from: https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/empfehlungen-risikogruppen-risikosituationen/impfprinzipien-imid-gastro.pdf.download.pdf/impfprinzipien-imid-gastro-de.pdf\n47 Bundesamt f\u00fcr Gesundheit (BAG) und Eidgen\u00f6ssische Kommission f\u00fcr Impffragen (EKIF). Impfprinzipien und Empfehlungen f\u00fcr Personen mit autoimmun-entz\u00fcndlichen rheumatischen Erkrankungen. BAG-Bulletin [Internet]. 2014 Feb 17 [cited 2022 Jan 15];8:159\u2013161. Available from: https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/empfehlungen-risikogruppen-risikosituationen/impfprinzipien-autoimmun-rheumatische-erkrankungen.pdf.download.pdf/bu-8-impfprinzipien-imid.pdf\n48 Diaz PS, Au D, Smith S, Amylon M, Link M, Smith S, et al. Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Pediatrics. 1991 Feb;87(2):166\u201370.\n49 Hall V, Johnson D, Torresi J. Travel and biologic therapy: travel-related infection risk, vaccine response and recommendations. J Travel Med. 2018 Jan;25(1).\n50 Goeijenbier M, van Genderen P, Ward BJ, Wilder-Smith A, Steffen R, Osterhaus AD. Travellers and influenza: risks and prevention. J Travel Med. 2017 Jan;24(1):taw078.\n51 Dekkiche S, de Valli\u00e8re S, D\u2019Acremont V, Genton B. Travel-related health risks in moderately and severely immunocompromised patients: a case-control study. J Travel Med. 2016 Feb;23(3):taw001.\n52 Schweizerisches Tropen- und Public Health-Institut [Internet]. Allschwil: Swiss TPH; c2022 [cited 2022 Dec 11]. Zentrum f\u00fcr Tropen- und Reisemedizin; [about 5 screens]. Available from: https://www.swisstph.ch/de/reisemedizin\n53 Antonini P, Beck B, Chappuis F, Eperon G, Haller S, Fehr J, et al; Schweizerisches Expertenkomitee f\u00fcr Reisemedizin (EKRM). Impfungen und Malariaschutz bei Auslandreisen: Empfehlungen Stand September 2021. BAG-Bulletin [Internet]. 2021 Oct 11 [cited 2022 Dec 11];41:8\u201363. Available from: https://www.infovac.ch/docs/public/voyageurs/reisemedizin-impfungen-und-malariaschutz-bei-auslandreisen--empfehlungen-stand-september-2021.pdf\n54 Schweizerische Akademie der Medizinischen Wissenschaften / Nationale Ethikkommission im Bereich der Humanmedizin. Autonomie in der Medizin: 7 Thesen [Internet]. Swiss Academies Communications 15(11). Bern: SAMW; 2020 [cited 2023 Feb 7]. Available from: https://www.samw.ch/dam/jcr:5d2f531d-d76c-4c2b-af35-4d8ef7db09ff/bericht_samw_autonomie_7_thesen.pdf\n55 Friedman MA, Winthrop KL. Vaccines and Disease-Modifying Antirheumatic Drugs\nPractical Implications for the Rheumatologist. Rheum Dis Clin N Am 43 (2017) 1\u201313 http://dx.doi.org/10.1016/j.rdc.2016.09.003\n56 Doran MF, Crowson CS, Pond GR, O\u2019Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002 Sep;46(9):2287\u201393.\n57 van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011 Mar;70(3):414\u201322.\n58 Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007 Dec;57(8):1431\u20138.\n59 Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, et al.; SABER Collaboration. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012 Aug;64(8):2773\u201380.\n60 Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S35\u201361.\n61 Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017 Oct;390(10103):1685\u201399.\n62 Ju\u00e1rez M, Misischia R, Alarc\u00f3n GS. Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Rheum Dis Clin North Am. 2003 Feb;29(1):163\u201384.\n63 Al-Rayes H, Al-Swailem R, Arfin M, Sobki S, Rizvi S, Tariq M. Systemic lupus erythematosus and infections: a retrospective study in Saudis. Lupus. 2007;16(9):755\u201363.\n64 Bongu A, Chang E, Ramsey-Goldman R. Can morbidity and mortality of SLE be improved? Best Pract Res Clin Rheumatol. 2002 Apr;16(2):313\u201332.\n65 Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016 Oct;75(10):1843\u20137.\n66 Tran CT, Ducancelle A, Masson C, Lunel-Fabiani F. Herpes zoster: risk and prevention during immunomodulating therapy. Joint Bone Spine. 2017 Jan;84(1):21\u20137.\n67 Yun H, Yang S, Chen L, Xie F, Winthrop K, Baddley JW, et al. Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: implications for Vaccination. Arthritis Rheumatol. 2016 Sep;68(9):2328\u201337.\n68 Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012 Jul;308(1):43\u20139.\n69 Marra F, Parhar K, Huang B, Vadlamudi N. Risk Factors for Herpes Zoster Infection: A Meta-Analysis. Open Forum Infect Dis. 2020 Jan;7(1):ofaa005.\n70 Migita K, Akeda Y, Akazawa M, Tohma S, Hirano F, Ideguchi H, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus. Arthritis Res Ther. 2015 Jun;17(1):149.\n71 Smatti MK, Cyprian FS, Nasrallah GK, Al Thani AA, Almishal RO, Yassine HM. Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms. Viruses. 2019 Aug;11(8):762.\n72 Arleevskaya MI, Manukyan G, Inoue R, Aminov R. Editorial: Microbial and Environmental Factors in Autoimmune and Inflammatory Diseases. Front Immunol. 2017 Mar;8:243.\n73 Baimukhamedov C, Barskova T, Matucci-Cerinic M. Arthritis after SARS-CoV-2 infection. Lancet Rheumatol. 2021 May;3(5):e324\u20135.\n74 Perrot L, Hemon M, Busnel JM, Muis-Pistor O, Picard C, Zandotti C, et al. First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection. Lancet Rheumatol. 2021 Jan;3(1):e6\u20138.\n75 Westra J, Rondaan C, van Assen S, Bijl M. Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol. 2015 Mar;11(3):135\u201345.\n76 Friedman MA, Curtis JR, Winthrop KL. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021 Oct;80(10):1255\u201365.\n77 Yokose C, McCormick N, Chen C, Neogi T, Chaisson C, Terkeltaub R, et al. Risk of gout flares after vaccination: a prospective case cross-over study. Ann Rheum Dis. 2019 Nov;78(11):1601\u20134.\n78 Sattui SE, Liew JW, Kennedy K, Sirotich E, Putman M, Moni TT, et al. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open. 2021 Sep;7(3):e001814.\n79 Machado PM, Lawson-Tovey S, Strangfeld A, Mateus EF, Hyrich KL, Gossec L, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2022 May;81(5):695\u2013709.\n80 Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis. 2002 Jul;61(7):623\u20135.\n81 Rahier JF, Moutschen M, Van Gompel A, Van Ranst M, Louis E, Segaert S, et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford). 2010 Oct;49(10):1815\u201327.\n82 Nakafero G, Grainge MJ, Myles PR, Mallen CD, Zhang W, Doherty M, et al. Association between inactivated influenza vaccine and primary care consultations for autoimmune rheumatic disease flares: a self-controlled case series study using data from the Clinical Practice Research Datalink. Ann Rheum Dis. 2019 Aug;78(8):1122\u20136.\n83 Lai SW, Kuo YH, Liao KF. Risk of gout flares after vaccination. Ann Rheum Dis. 2021 Aug;80(8):e137.\n84 Geisen UM, Berner DK, Tran F, S\u00fcmb\u00fcl M, Vullriede L, Ciripoi M, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. 2021 Oct;80(10):1306\u201311.\n85 LaCasce AS. Therapeutic use and toxicity of high-dose methotrexate [Internet]. Alphen aan den Rijn: Wolters Kluwer N.V.; c2023 [cited 2022 Jan 15]. Available from: https://www.uptodate.com/contents/therapeutic-use-and-toxicity-of-high-dose-methotrexate?search=methotrexat&source=search_result&selectedTitle=4~148&usage_type=default&display_rank=3.\n86 Segal BH, Sneller MC. Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin North Am. 1997 May;23(2):219\u201337.\n87 Schweizerische Gesellschaft f\u00fcr Rheumatologie. Impfempfehlungen f\u00fcr Patienten mit entz\u00fcndlich-rheumatischen Erkrankungen [Internet]. Z\u00fcrich: SGR; 2020 [cited 2023 Feb 7]. Available from: https://www.rheuma-net.ch/images/pdf/DEUTSCH/Impfempfehlungen_10-2020_D_Def.pdf\n88 Eperon G, Vaudaux B. Vaccination chez le voyageur immunosupprim\u00e9 [Immunization for the immunosuppressed traveler] [French.]. Rev Med Suisse. 2013 May;9(385):970\u20138.\n89 Oliveira AC, Mota LM, Santos-Neto LL, Sim\u00f5es M, Martins-Filho OA, Tauil PL. Seroconversion in patients with rheumatic diseases treated with immunomodulators or immunosuppressants, who were inadvertently revaccinated against yellow fever. Arthritis Rheumatol. 2015 Feb;67(2):582\u20133.\n90 Dos Reis BS, Staub FC, Koishi A, Zanluca C, Dos Santos CN, Skare TL, et al. Seroconversion of rheumatoid arthritis patients after yellow fever vaccination. Clin Rheumatol. 2022 Mar;41(3):705\u20138.\n91 Park JK, Lee YJ, Shin K, Ha YJ, Lee EY, Song YW, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2018 Jun;77(6):898\u2013904.\n92 Park JK, Lee YJ, Shin K, Kang EH, Ha YJ, Park JW, et al. A Multicenter, Prospective, Randomized, Parallel-Group Trial on the Effects of Temporary Methotrexate Discontinuation for One Week Versus Two Weeks on Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2023 Feb;75(2):171\u20137.\n93 Abhishek A, Boyton RJ, Peckham N, McKnight \u00c1, Coates LC, Bluett J, et al.; VROOM study investigators. Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial. Lancet Respir Med. 2022 Sep;10(9):840\u201350.\n94 Sparks JA, Tedeschi SK. Improving COVID-19 vaccine immunogenicity by interrupting methotrexate treatment. Lancet Respir Med. 2022 Sep;10(9):813\u20135.\n95 Medeiros-Ribeiro AC, Aikawa NE. Discontinuing methotrexate to enhance vaccine response. Nat Rev Rheumatol. 2022 Sep;18(9):497\u20138.\n96 Bordeianou L, Yeh DD. Etiologies, clinical manifestations, and diagnosis of mechanical small bowel obstruction in adults [Internet]. Alphen aan den Rijn: Wolters Kluwer N.V.; c2023 [cited 2022 Jan 15]. Available from: https://www.uptodate.com/contents/etiologies-clinical-manifestations-and-diagnosis-of-mechanical-small-bowel-obstruction-in-adults?search=chronische%20darmerkrankung&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1\n97 Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al.; European Crohn\u2019s and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn\u2019s Colitis. 2014 Jun;8(6):443\u201368.\n98 Werlin SL, Grand RJ. Severe colitis in children and adolescents: diagnosis. Course, and treatment. Gastroenterology. 1977 Oct;73(4 Pt 1):828\u201332.\n99 Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT; AGA Institute Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-\u03b1 biologic drugs for the induction and maintenance of remission in inflammatory Crohn\u2019s disease. Gastroenterology. 2013 Dec;145(6):1459\u201363.\n100 Prentice RE, Rentsch C, Al-Ani AH, Zhang E, Johnson D, Halliday J, et al. SARS-CoV-2 vaccination in patients with inflammatory bowel disease. GastroHep. 2021 Jul;3(4):212\u201328.\n101 Alexander JL, Moran GW, Gaya DR, Raine T, Hart A, Kennedy NA, et al.; Inflammatory Bowel Disease section of the British Society of Gastroenterology and the the Inflammatory Bowel Disease Clinical Research Group. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol. 2021 Mar;6(3):218\u201324.\n102 Siegel CA, Melmed GY, McGovern DP, Rai V, Krammer F, Rubin DT, et al.; International Organization for the Study of Inflammatory Bowel Disease (IOIBD); International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021 Apr;70(4):635\u201340.\n103 Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008 Apr;134(4):929\u201336.\n104 Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2017; 112:241\u2013258; doi:10.1038/ajg.2016.537\n105 Bundesamt f\u00fcr Gesundheit (BAG) und Eidgen\u00f6ssische Kommission f\u00fcr Impffragen (EKIF). Empfehlung einer Auffrischimpfung gegen Covid-19 mit einem mRNA-Impfstoff (Stand 21.12.21) [Internet]. Bern: BAG; 2021 [cited 2022 Jan 15]. Available from: https://www.bag.admin.ch/dam/bag/de/dokumente/mt/k-und-i/aktuelle-ausbrueche-pandemien/2019-nCoV/impfempfehlung-auffrischimpfung-mrna.pdf.download.pdf/Covid%2019_Empfehlung%20einer%20Auffrischimpfung%20mit%20einem%20mRNA-Impfstoff_04.11.21.pdf\n106 Bundesamt f\u00fcr Gesundheit (BAG) und Eidgen\u00f6ssische Kommission f\u00fcr Impffragen (EKIF). Impfempfehlung f\u00fcr mRNA-Impfstoffe gegen Covid-19 (Stand 21.12.21) [Internet]. Bern: BAG; 2021 [updated 2022 May 23; cited 2022 Jan 15]. Available from: https://www.bag.admin.ch/dam/bag/de/dokumente/mt/k-und-i/aktuelle-ausbrueche-pandemien/2019-nCoV/impfempfehlung-covid-19.pdf.download.pdf/Impfempfehlung%20f%C3%BCr%20mRNA-Impfstoffe%20gegen%20Covid-19.pdf.\n107 D\u2019Amico F, Rabaud C, Peyrin-Biroulet L, Danese S. SARS-CoV-2 vaccination in IBD: more pros than cons. Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):211\u20133.\n108 Centers for Disease Control and Prevention, Advisory Committee for Immunization Practices. Altered Immunocompetence. General Best Practice Guidelines for Immunization, 10.2.2023. available from: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html\n109 Caldera F, Misch EA, Saha S, Wald A, Zhang Y, Hubers J, et al. Immunosuppression Does Not Affect Antibody Concentrations to Measles, Mumps, and Rubella in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2019 Jan;64(1):189\u201395.\n110 Nabizadeh F, Ramezannezhad E, Kazemzadeh K, Khalili E, Ghaffary EM, Mirmosayyeb O. Multiple sclerosis relapse after COVID-19 vaccination: A case report-based systematic review. J Clin Neurosci. 2022 Oct;104:118\u201325.\n111 Madelon N, Heikkil\u00e4 N, Sabater Royo I, Fontannaz P, Breville G, Lauper K, et al. Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab. JAMA Neurol. 2022 Apr;79(4):399\u2013404.\n112 Mailand MT, Frederiksen JL. Vaccines and multiple sclerosis: a systematic review. J Neurol. 2017 Jun;264(6):1035\u201350.\n113 Confavreux C, Suissa S, Saddier P, Bourd\u00e8s V, Vukusic S; Vaccines in Multiple Sclerosis Study Group. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med. 2001 Feb;344(5):319\u201326.\n114 Ascherio A, Zhang SM, Hern\u00e1n MA, Olek MJ, Coplan PM, Brodovicz K, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med. 2001 Feb;344(5):327\u201332.\n115 De Keyser J, Zwanikken C, Boon M. Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci. 1998 Jul;159(1):51\u20133.\n116 Oikonen M, Laaksonen M, Aalto V, Ilonen J, Salonen R, Er\u00e4linna JP, et al. Temporal relationship between environmental influenza A and Epstein-Barr viral infections and high multiple sclerosis relapse occurrence. Mult Scler. 2011 Jun;17(6):672\u201380.\n117 Bonds AM, Novick TK, Dietert JB, Araghizadeh FY, Olson CH. Incisional negative pressure wound therapy significantly reduces surgical site infection in open colorectal surgery. Dis Colon Rectum. 2013 Dec;56(12):1403\u20138.\n118 Malone DL, Genuit T, Tracy JK, Gannon C, Napolitano LM. Surgical site infections: reanalysis of risk factors. J Surg Res. 2002 Mar;103(1):89\u201395.\n119 Olsen MA, Lock-Buckley P, Hopkins D, Polish LB, Sundt TM, Fraser VJ. The risk factors for deep and superficial chest surgical-site infections after coronary artery bypass graft surgery are different. J Thorac Cardiovasc Surg. 2002 Jul;124(1):136\u201345.\n120 Muller LM, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AI, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005 Aug;41(3):281\u20138.\n121 Akash MS, Rehman K, Fiayyaz F, Sabir S, Khurshid M. Diabetes-associated infections: development of antimicrobial resistance and possible treatment strategies. Arch Microbiol. 2020 Jul;202(5):953\u201365.\n122 Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab. 2012 Mar;16 Suppl 1(Suppl1):S27\u201336.\n123 Ilyas R, Wallis R, Soilleux EJ, Townsend P, Zehnder D, Tan BK, et al. High glucose disrupts oligosaccharide recognition function via competitive inhibition: a potential mechanism for immune dysregulation in diabetes mellitus. Immunobiology. 2011;216(1-2):126\u201331.\n124 Wiedermann U, Sitte HH, Burgmann H, Eser A, Falb P, Holzmann H, et al. Impfungen bei Immundefekten/Immunsuppression - Expertenstatement und Empfehlungen. Wien Klin Wochenschr. 2016 Aug;128(S4 Suppl 4):337\u201376.\n125 Allard R, Leclerc P, Tremblay C, Tannenbaum TN. Diabetes and the severity of pandemic influenza A (H1N1) infection. Diabetes Care. 2010 Jul;33(7):1491\u20133.\n126 Critchley JA, Carey IM, Harris T, DeWilde S, Hosking FJ, Cook DG. Glycemic Control and Risk of Infections Among People With Type 1 or Type 2 Diabetes in a Large Primary Care Cohort Study. Diabetes Care. 2018 Oct;41(10):2127\u201335.\n127 Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020 Jun;31(6):1068\u20131077.e3.\n128 Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med. 2007 Oct;357(14):1373\u201381.\n129 Looijmans-Van den Akker I, Verheij TJ, Buskens E, Nichol KL, Rutten GE, Hak E. Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients. Diabetes Care. 2006 Aug;29(8):1771\u20136.\n130 Lau D, Eurich DT, Majumdar SR, Katz A, Johnson JA. Working-age adults with diabetes experience greater susceptibility to seasonal influenza: a population-based cohort study. Diabetologia. 2014 Apr;57(4):690\u20138.\n131 Husein N, Chetty A; Diabetes Canada Clinical Practice Guidelines Expert Committee. Influenza, Pneumococcal, Hepatitis B and Herpes Zoster Vaccinations. Can J Diabetes. 2018 Apr;42 Suppl 1:S142\u20134.\n132 Kornum JB, Thomsen RW, Riis A, Lervang HH, Sch\u00f8nheyder HC, S\u00f8rensen HT. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care. 2008 Aug;31(8):1541\u20135.\n133 Okamoto S, Hata A, Sadaoka K, Yamanishi K, Mori Y. Comparison of varicella-zoster virus-specific immunity of patients with diabetes mellitus and healthy individuals. J Infect Dis. 2009 Nov;200(10):1606\u201310.\n134 Heymann AD, Chodick G, Karpati T, Kamer L, Kremer E, Green MS, et al. Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection. 2008 Jun;36(3):226\u201330.\n135 Bundesamt f\u00fcr Gesundheit (BAG) und Eidgen\u00f6ssische Kommission f\u00fcr Impffragen (EKIF). BAG-Bulletin [Internet]. 2021 Nov 22 [cited 2022 Apr 3]:47. Available from: https://www.bag.admin.ch/dam/bag/de/dokumente/cc/Kampagnen/Bulletin/2021/bu-47-21.pdf.download.pdf/BU_47_21_DE.pdf.\n136 Salvadori MI, Price VE; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Preventing and treating infections in children with asplenia or hyposplenia. Paediatr Child Health. 2014 May;19(5):271\u20138.\n137 Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among post-splenectomy patients. J Infect. 2001 Oct;43(3):182\u20136.\n138 Aavitsland P, Fr\u00f8holm LO, H\u00f8iby EA, Lystad A. Risk of pneumococcal disease in individuals without a spleen. Lancet. 1994 Nov;344(8935):1504.\n139 El-Alfy MS, El-Sayed MH. Overwhelming postsplenectomy infection: is quality of patient knowledge enough for prevention? Hematol J. 2004;5(1):77\u201380.\n140 Siebert JN, Posfay-Barbe KM, Habre W, Siegrist CA. Influence of anesthesia on immune responses and its effect on vaccination in children: review of evidence. Paediatr Anaesth. 2007 May;17(5):410\u201320.\n141 Bundesamt f\u00fcr Gesundheit (BAG), Schweizerische Kommission f\u00fcr Impffragen (EKIF). Pr\u00e4vention schwerer Infektionen bei anatomischer oder funktioneller Asplenie. BAG-Bulletin [Internet]. 2015 Mar 2 [cited 2022 Jan 15];10:155\u2013162. Available from: https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/empfehlungen-spezifische-erreger-krankheiten/pneumokokken/asplenie-praevention-infektion-anatomischer-funktioneller.pdf.download.pdf/bu-10-15-asplenie-praevention.pdf\n142 Collins S, Ramsay M, Campbell H, Slack MP, Ladhani SN. Invasive Haemophilus influenzae type b disease in England and Wales: who is at risk after 2 decades of routine childhood vaccination? Clin Infect Dis. 2013 Dec;57(12):1715\u201321.\n143 Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007 Dec;357(25):2601\u201314.\n144 Bundesamt f\u00fcr Gesundheit (BAG) und Eidgen\u00f6ssische Kommission f\u00fcr Impffragen (EKIF). Impfempfehlungen f\u00fcr Personen vor und nach Transplantation eines soliden Organs. BAG-Bulletin [Internet]. 2014 Feb 17 [cited 2022 May 28];8:155\u2013158. Available from: https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/empfehlungen-risikogruppen-risikosituationen/impfempfehlungen-transplantation-solides-organ.pdf.download.pdf/bu-8-impfempfehlungen-sot.pdf\n145 Danziger-Isakov L, Kumar D; AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant. 2019 Sep;33(9):e13563.\n146 Kumar D, Michaels MG, Morris MI, Green M, Avery RK, Liu C, et al.; American Society of Transplantation H1N1 Collaborative Study Group. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis. 2010 Aug;10(8):521\u20136.\n147 Pergam SA, Limaye AP; AST Infectious Diseases Community of Practice. Varicella zoster virus in solid organ transplantation. Am J Transplant. 2013 Mar;13 Suppl 4(Suppl 4):138-46.\n148 Kidd IM, Booth CJ, Rigden SP, Tong CY, MacMahon EM. Measles-associated encephalitis in children with renal transplants: a predictable effect of waning herd immunity? Lancet. 2003 Sep;362(9386):832.\n149 Linnemann CC Jr, First MR. Risk of pneumococcal infections in renal transplant patients. JAMA. 1979 Jun;241(24):2619\u201321.\n150 British Transplantation Society. Guidelines for Hepatitis B & Solid Organ Transplantation [Internet]. Sheffield: The Society; 2018 [cited 2023 Feb 7]. Available from: https://bts.org.uk/wp-content/uploads/2018/03/BTS_HepB_Guidelines_FINAL_09.03.18.pdf.\n151 Aslam S, Adler E, Mekeel K, Little SJ. Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients. Transpl Infect Dis. 2021 Oct;23(5):e13705.\n152 Nailescu C, Ermel AC, Shew ML. Human papillomavirus-related cancer risk for solid organ transplant recipients during adult life and early prevention strategies during childhood and adolescence. Pediatr Transplant. 2022 Nov;26(7):e14341.\n153 Eckerle I, Rosenberger KD, Zwahlen M, Junghanss T. Serologic vaccination response after solid organ transplantation: a systematic review. PLoS One. 2013;8(2):e56974.\n154 Mulley WR, Dendle C, Ling JE, Knight SR. Does vaccination in solid-organ transplant recipients result in adverse immunologic sequelae? A systematic review and meta-analysis. J Heart Lung Transplant. 2018 Jul;37(7):844\u201352.\n155 Croce E, Hatz C, Jonker EF, Visser LG, Jaeger VK, B\u00fchler S. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports. Vaccine. 2017 Mar;35(9):1216\u201326.\n156 P\u00e9rez-Romero P, Bulnes-Ramos A, Torre-Cisneros J, Gavald\u00e1 J, Aydillo TA, Moreno A, et al.; Influenza Vaccine in Solid Organ Transplant Recipient Study Group, Spanish Network of Research in Infectious Diseases (REIPI-GESITRA); Influenza Vaccine in Solid Organ Transplant Recipient Study Group Spanish Network of Research in Infectious Diseases REIPI-GESITRA. Influenza vaccination during the first 6 months after solid organ transplantation is efficacious and safe. Clin Microbiol Infect. 2015 Nov;21(11):1040.e11\u20138.\n157 Dos Santos G, Haguinet F, Cohet C, Webb D, Logie J, Ferreira GL, et al. Risk of solid organ transplant rejection following vaccination with seasonal trivalent inactivated influenza vaccines in England: A self-controlled case-series. Vaccine. 2016 Jun;34(31):3598\u2013606.\n158 Avery RK. Influenza vaccines in the setting of solid-organ transplantation: are they safe? Curr Opin Infect Dis. 2012 Aug;25(4):464\u20138.\n159 Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med. 2020 Aug;17(3):519\u201327.\n160 Gil L, Styczynski J, Komarnicki M. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome. Infection. 2007 Dec;35(6):421\u20137.\n161 Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol. 2010 Mar;23(1):145\u201353.\n162 Reich G, Mapara MY, Reichardt P, D\u00f6rken B, Maschmeyer G. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant. 2001 Mar;27(5):525\u20139.\n163 Patel SR, Bate J, Borrow R, Heath PT. Serotype-specific pneumococcal antibody concentrations in children treated for acute leukaemia. Arch Dis Child. 2012 Jan;97(1):46\u20138.\n164 Park H, Youk J, Kim HR, Koh Y, Kwon JH, Yoon SS, et al. Infectious complications in multiple myeloma receiving autologous stem cell transplantation in the past 10 years. Int J Hematol. 2017 Dec;106(6):801\u201310.\n165 Najjar I, Paluca F, Loukidis K, Tarr PE. Recurrent Campylobacter Enteritis in Patients with Hypogammaglobulinemia: review of the Literature. J Clin Med. 2020 Feb;9(2):553.\n166 Owayed A, Al-Herz W. Sinopulmonary Complications in Subjects With Primary Immunodeficiency. Respir Care. 2016 Aug;61(8):1067\u201372.\n167 Ravandi F, O\u2019Brien S. Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother. 2006 Feb;55(2):197\u2013209.\n168 Tadmor T, Welslau M, Hus I. A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia. Expert Rev Hematol. 2018 Jan;11(1):57\u201370.\n169 Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bj\u00f6rkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015 Jan;100(1):107\u201313.\n170 Bonelli MM, Mrak D, Perkmann T, Haslacher H, Aletaha D. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. Ann Rheum Dis. 2021 Oct;80(10):1355\u20136.\n171 Siber GR, Werner BG, Halsey NA, Reid R, Almeido-Hill J, Garrett SC, et al. Interference of immune globulin with measles and rubella immunization. J Pediatr. 1993 Feb;122(2):204\u201311.\n172 National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP) [Erratum in: MMWR Recomm Rep. 2011 Jul 29;60:993]. MMWR Recomm Rep. 2011 Jan;60(2):1\u201364.\n173 Public Health Agency of Canada. Blood products, human immunoglobulin and timing of immunization: Canadian Immunization Guide [Internet]. Ottawa: The Agency; 2013 [updated 2020; cited 2022 Jan 15]. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-11-blood-products-human-immune-globulin-timing-immunization.html\n174 Wijn DH, Groeneveld GH, Vollaard AM, Muller M, Wallinga J, Gelderblom H, et al. Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events. Eur J Cancer. 2018 Nov;104:182\u20137.\n175 Gwynn ME, DeRemer DL, Saunders KM, Parikh J, Bollag RJ, Clemmons AB. Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors. J Oncol Pharm Pract. 2020 Apr;26(3):647\u201354.\n176 Chong CR, Park VJ, Cohen B, Postow MA, Wolchok JD, Kamboj M. Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors. Clin Infect Dis. 2020 Jan;70(2):193\u20139.\n177 Gambichler T, Reuther J, Scheel CH, Becker JC. On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19 [Erratum in: J Immunother Cancer. 2021 Apr;9] [4]. J Immunother Cancer. 2020 Jul;8(2):e001145.\n178 L\u00e4ubli H, Balmelli C, Kaufmann L, Stanczak M, Syedbasha M, Vogt D, et al. Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. J Immunother Cancer. 2018 May 22;6(1):40.\n179 Chong CR, Park VJ, Cohen B, Postow MA, Wolchok JD, Kamboj M. Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors. Clin Infect Dis. 2020 Jan;70(2):193\u20139.\n180 Barra A, Cordonnier C, Preziosi MP, Intrator L, Hessel L, Fritzell B, et al. Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients. J Infect Dis. 1992 Nov;166(5):1021\u20138.\n181 Harris AE, Styczynski J, Bodge M, Mohty M, Savani BN, Ljungman P. Pretransplant vaccinations in allogeneic stem cell transplantation donors and recipients: an often-missed opportunity for immunoprotection? Bone Marrow Transplant. 2015 Jul;50(7):899\u2013903.\n182 Youssef S, Rodriguez G, Rolston KV, Champlin RE, Raad II, Safdar A. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989-2005. Medicine (Baltimore). 2007 Mar;86(2):69\u201377.\n183 Engelhard D, Cordonnier C, Shaw PJ, Parkalli T, Guenther C, Martino R, et al.; Infectious Disease Working Party of the European Bone Marrow Transplantation (IDWP-EBMT). Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol. 2002 May;117(2):444\u201350.\n184 Parkman R, Weinberg KI. Immunological reconstitution following bone marrow transplantation. Immunol Rev. 1997 Jun;157(1):73\u20138.\n185 Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study [Erratum in: Lancet Haematol. 2021 Jun;8] [6] [:e393]. Lancet Haematol. 2021 Mar;8(3):e185\u201393.\n186 Goldman JD, Robinson PC, Uldrick TS, Ljungman P. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. J Immunother Cancer. 2021 Jun;9(6):e002630.\n187 Linnik J, Syedbasha M, Kaltenbach HM, Vogt D, Hollenstein Y, Kaufmann L, et al. Association of Host Factors With Antibody Response to Seasonal Influenza Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Patients. J Infect Dis. 2022 Apr;225(8):1482\u201393.\n188 Pelton SI, Shea KM, Farkouh RA, Strutton DR, Braun S, Jacob C, et al. Rates of pneumonia among children and adults with chronic medical conditions in Germany. BMC Infect Dis. 2015 Oct;15(1):470.\n189 Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1526\u201333.\n190 DaRoza G, Loewen A, Djurdjev O, Love J, Kempston C, Burnett S, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis. 2003 Dec;42(6):1184\u201392.\n191 Bond TC, Spaulding AC, Krisher J, McClellan W. Mortality of dialysis patients according to influenza and pneumococcal vaccination status. Am J Kidney Dis. 2012 Dec;60(6):959\u201365.\n192 Bundesamt f\u00fcr Gesundheit (BAG) und Eidgen\u00f6ssische Kommission f\u00fcr Impffragen (EKIF). Analyserahmen und Empfehlungen zur Impfung gegen Affenpocken, Impfstoff MVA-BN\u00ae (Modified Vaccinia Ankara von Bavarian Nordic) [Internet]. Bern: BAG; 2022 Sep 1 [cited 2022 Dec 11]. Available from: https://www.bag.admin.ch/dam/bag/de/dokumente/cc/kom/impfempfehlungen.pdf.download.pdf/Analyserahmen%20und%20Empfehlungen%20zur%20Impfung%20gegen%20Affenpocken.pdf.\n193 Simon NR, Sch\u00f6pf IC, Haerry D, Deml MJ, M\u00fcller S, Aebi-Popp K, et al. Affenpocken. Prim and Hosp Care [Internet]. 2022 Oct 5;22(10):[7 p.]. Available from: https://primary-hospital-care.ch/article/doi/phc-d.2022.10529\n194 Wasan SK, Calderwood AH, Long MD, Kappelman MD, Sandler RS, Farraye FA. Immunization rates and vaccine beliefs among patients with inflammatory bowel disease: an opportunity for improvement. Inflamm Bowel Dis. 2014 Feb;20(2):246\u201350.\n195 Hmamouchi I, Winthrop K, Launay O, Dougados M. Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort. Vaccine. 2015 Mar;33(12):1446\u201352.\n196 Pug\u00e8s M, Biscay P, Barnetche T, Truchetet M\u00c9, Richez C, Seneschal J, et al. Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis. Rheumatology (Oxford). 2016 Sep;55(9):1664\u201372.\n197 Dietrich L, Abreu De Azevedo M, Wirz S, Deml MJ, Schmid-Thurneysen L, Fr\u00f6hlich J. Grippeimpfung: Kritische Beurteilung und praktische Empfehlungen. Prim Hosp Care [Internet]. 2021 Feb 3 [cited 2022 May 7];21(2):52\u201359. Available from: https://primary-hospital-care.ch/article/doi/phc-d.2021.10341.\n198 Bitterman R, Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev. 2018 Feb;2(2):CD008983.\n199 van Aalst M, Garcia Garrido HM, van der Leun J, Meek B, van Leeuwen EM, L\u00f6wenberg M, et al. Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients With Inflammatory Bowel Disease. Clin Infect Dis. 2020 Feb;70(4):595\u2013604.\n200 Dendle C, Stuart RL, Mulley WR, Holdsworth SR. Pneumococcal vaccination in adult solid organ transplant recipients: A review of current evidence. Vaccine. 2018 Oct;36(42):6253\u201361.\n201 Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Mansfield K, et al. Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: A cohort study. Neurology. 2016 Jul;87(1):94\u2013102.\n202 Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009 Feb;301(7):737\u201344.\n203 Blank LJ, Polydefkis MJ, Moore RD, Gebo KA. Herpes zoster among persons living with HIV in the current antiretroviral therapy era. J Acquir Immune Defic Syndr. 2012 Oct;61(2):203\u20137.\n204 Chen HH, Chen YM, Chen TJ, Lan JL, Lin CH, Chen DY. Risk of herpes zoster in patients with systemic lupus erythematosus: a three-year follow-up study using a nationwide population-based cohort [Erratum in: Clinics ] [Sao Paulo] [. 2012 Sep;67] [9]. Clinics (S\u00e3o Paulo). 2011;66(7):1177\u201382.\n205 Kawai K, Yawn BP. Risk Factors for Herpes Zoster: A Systematic Review and Meta-analysis. Mayo Clin Proc. 2017; 92(12):1806\u20131821.\n206 Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, et al.; Zoster-039 study group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, andomized, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019 Sep;19(9):988\u20131000. andomized\n207 Vink P, Delgado Mingorance I, Maximiano Alonso C, Rubio-Viqueira B, Jung KH, Rodriguez Moreno JF, et al.; Zoster-028 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial. Cancer. 2019 Apr;125(8):1301\u201312.\n208 Miller G. Vaccine Prevention of Herpes Zoster in Organ Transplant Recipients: A Busy Intersection of Immune Responses to Foreign Antigens. Clin Infect Dis. 2020 Jan;70(2):191\u20132.\n209 Barghash MH, Taimur S, Rana M, Behar J, Mancini DM. Recombinant herpes zoster vaccine after heart transplantation: A single-center experience. J Heart Lung Transplant. 2020 Dec;39(12):1501\u20133.\n210 Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, Demissie EG, et al. Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study. Ann Intern Med. 2021 Nov;174(11):1572\u201385.\n211 Hindson J. Immunosuppressive IBD drugs and COVID-19 vaccine immunogenicity. Nat Rev Gastroenterol Hepatol. 2022 Apr;19(4):216.\n212 Collier AY, Yu J, McMahan K, Liu J, Atyeo C, Ansel JL, et al. Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals. J Infect Dis. 2022 Apr;225(7):1124\u20138.\n213 Jena A, Mishra S, Deepak P, Kumar-M P, Sharma A, Patel YI, et al. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis. Autoimmun Rev. 2022 Jan;21(1):102927.\n214 Werbel WA, Boyarsky BJ, Ou MT, Massie AB, Tobian AA, Garonzik-Wang JM, et al. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Ann Intern Med. 2021 Sep;174(9):1330\u20132.\n215 Speich B, Chammartin F, Abela IA, Amico P, Stoeckle MP, Eichenberger AL, et al.; Swiss HIV Cohort Study and the Swiss Transplant Cohort Study. Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial. Clin Infect Dis. 2022 Aug;75(1):e585\u201393.\n216 Turner JS, Kim W, Kalaidina E, Goss CW, Rauseo AM, Schmitz AJ, et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature. 2021 Jul;595(7867):421\u20135.\n217 Hilty MP, Keiser S, Wendel Garcia PD, Moser A, Schuepbach RA, Hilty MP, et al.; RISC-19-ICU Investigators for Switzerland. mRNA-based SARS-CoV-2 vaccination is associated with reduced ICU admission rate and disease severity in critically ill COVID-19 patients treated in Switzerland. Intensive Care Med. 2022 Mar;48(3):362\u20135.\n218 Pilishvili T, Gierke R, Fleming-Dutra KE, Farrar JL, Mohr NM, Talan DA, et al.; Vaccine Effectiveness among Healthcare Personnel Study Team. Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel. N Engl J Med. 2021 Dec;385(25):e90.\n219 Hall VG, Ferreira VH, Ku T, Ierullo M, Majchrzak-Kita B, Chaparro C, et al. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. N Engl J Med. 2021 Sep;385(13):1244\u20136.\n220 Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. N Engl J Med. 2021 Aug ;385(7) :661\u20132.\n221 Pham T, Claudepierre P, Constantin A, Fautrel B, Gossec L, Gottenberg JE, et al. Abatacept therapy and safety management. Joint Bone Spine. 2009 May;76 Suppl 1:S3\u201355.\n222 Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020 Aug;136(8):925\u201335.\n223 Wang Y, Li C, Xia J, Li P, Cao J, Pan B, et al. Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. Blood Adv. 2021 Dec;5(23):5290\u20139.\n224 Bhoj VG, Arhontoulis D, Wertheim G, Capobianchi J, Callahan CA, Ellebrecht CT, et al. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood. 2016 Jul;128(3):360\u201370.\n225 Bersanelli M, Buti S, De Giorgi U, Di Maio M, Giannarelli D, Pignata S, et al. State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: when common sense is not enough. Crit Rev Oncol Hematol. 2019 Jul;139:87\u201390.\n226 Kang CK, Kim HR, Song KH, Keam B, Choi SJ, Choe PG, et al. Cell-Mediated Immunogenicity of Influenza Vaccination in Patients With Cancer Receiving Immune Checkpoint Inhibitors. J Infect Dis. 2020 Nov;222(11):1902\u20139.\n227 European Medicines Agency [Internet]. Amsterdam: The Agency; c1995\u20132023 [cited 2023 Feb 8]. Taltz, INN-Ixekizumab; [121 p.].. Available from: https://www.ema.europa.eu/en/documents/product-information/taltz-epar-product-information_de.pdf\n228 European Medicines Agency [Internet]. Amsterdam: The Agency; c1995\u20132023 [cited 2023 Feb 8]. Rinvoq, INN-Upadacitinib; [110 p.]. Available from: https://www.ema.europa.eu/en/documents/product-information/rinvoq-epar-product-information_de.pdf.\n229 Askling J, Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol. 2008 Mar;20(2):138\u201344.\n230 Veit O, Domingo C, Niedrig M, Staehelin C, Sonderegger B, H\u00e9quet D, et al.; Swiss HIV Cohort Study. Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination Schedule. Clin Infect Dis. 2018 Mar;66(7):1099\u2013108.\n231 Veit O, Niedrig M, Chapuis-Taillard C, Cavassini M, Mossdorf E, Schmid P, et al.; Swiss HIV Cohort Study. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis. 2009 Mar;48(5):659\u201366.\n232 Mufson MA, Hughey DF, Turner CE, Schiffman G. Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination. Vaccine. 1991 Jun;9(6):403\u20137.\n233 Musher DM, Groover JE, Rowland JM, Watson DA, Struewing JB, Baughn RE, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin Infect Dis. 1993 Jul;17(1):66\u201373.\n234 Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis. 2008 Oct;198(7):1019\u201327.\n235 Bundesamt f\u00fcr Gesundheit (BAG). Anpassungen der Impfempfehlungen zum Schutz vor invasiven Meningokokken-Erkrankungen. BAG-Bulletin [Internet]. 2018 Nov 12 [cited 2022 Jan 15];46:14\u201321.Available from: https://www.bag.admin.ch/dam/bag/de/dokumente/kuv-leistungen/referenzdokumente-klv/12a-bst-g-meningokokken-impfung-bulletin4618.pdf.download.pdf/Art.%2012a%20Bst.g%20Meningokokken-Impfung,%20Empfehlungen%20BAG%20und%20EKIF%20vom%2012.11.2018,%20BAG-Bulletin%20Nr.%2046%2018.pdf\n236 Bundesamt f\u00fcr Gesundheit (BAG). Erg\u00e4nzung der Meningokokken-Impfempfehlung: Meningokokken-B-Impfung f\u00fcr Personen mit erh\u00f6htem Erkrankungsrisiko. BAG-Bulletin [Internet]. 2022 May 23 [cited 2022 Dec 12];21:8\u201314. Available from: https://www.bag.admin.ch/dam/bag/de/dokumente/mt/infektionskrankheiten/meningokokken/ergaenzung-empf-meningokokken-b-impfung-risikopersonen.pdf.download.pdf/BU_21_22_DE_Meningokokkken.pdf.\n237 Rieger CT, Liss B, Mellinghoff S, Buchheidt D, Cornely OA, Egerer G, et al.; German Society of Hematology and Medical Oncology Infectious Diseases Working Group (AGIHO). Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Oncol. 2018 Jun;29(6):1354\u201365.", "language": null, "image": null, "pagetype": "article", "links": ["https://www.swisshealthweb.ch/de/newsfeed/", "https://phc.swisshealthweb.ch/de/", "#collapseSearch", "/de/article/doi/phc-d.2023.10707/", "/fr/article/doi/phc-f.2023.10707/", "https://www.swisshealthweb.ch/de/newsfeed/", "https://phc.swisshealthweb.ch/de/", "/de/", "/de/aktuelle-ausgabe/", "/de/archiv/", "/de/publizieren/", "/de/ueber-phc/", "https://www.swisshealthweb.ch/de/zeitschriften/", "https://shop.emh.ch/", "https://www.swisshealthweb.ch/de/encyclomed/", "https://events.emh.ch", "https://phc.swisshealthweb.ch/de/article/?tx_cs2services_teaser%5Baction%5D=serviceLinkHandler&tx_cs2services_teaser%5Bcontroller%5D=Services&tx_cs2services_teaser%5Bservice%5D=9&type=96529&cHash=957c22557b087f72957914479c8387b5", "https://jobs.saez.ch/de", "https://market.swisshealthweb.ch/de/", null, "tel:+410614678555", "#", "https://www.swisshealthweb.ch/de/newsfeed/", "/de/article/doi/phc-d.2023.10707/", "/fr/article/doi/phc-f.2023.10707/", "https://events.emh.ch/", "https://jobs.saez.ch/de", "https://market.swisshealthweb.ch/de/", "https://shop.emh.ch/", null, "/de/selected-filter/attribute/Fort-%20%26%20Weiterbildung/", "/de/selected-filter/subjectarea/Allgemeine%20Innere%20Medizin/", "/de/selected-filter/subjectarea/Infektiologie/", "javascript:void(0)", "https://phc.swisshealthweb.ch/fileadmin/assets/PHC/2023/phc-d.2023.10707/phc-d-2023-10707.pdf", "/de/selected-filter/attribute/Fort-%20%26%20Weiterbildung/", "/de/selected-filter/subjectarea/Allgemeine%20Innere%20Medizin/", "/de/selected-filter/subjectarea/Infektiologie/", "#otherInfos", "/de/archiv/ausgabe/issue-doi/phc.2023.09/", "https://doi.org/10.4414/phc-d.2023.10707", "https://www.swisshealthweb.ch/de/encyclomed/products/substance/200157/", "https://www.swisshealthweb.ch/de/encyclomed/products/substance/200845/", "https://www.swisshealthweb.ch/de/encyclomed/products/substance/200930/", "https://www.swisshealthweb.ch/de/encyclomed/products/substance/201159/", "https://www.swisshealthweb.ch/de/encyclomed/products/substance/201429/", "javascript:void(0)", "https://phc.swisshealthweb.ch/fileadmin/assets/PHC/2023/phc-d.2023.10707/phc-d-2023-10707.pdf", "https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/allgemeine-empfehlungen/schweizerischer-impfplan.pdf.download.pdf/schweizerischer-impfplan-de.pdf", "https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/empfehlungen-risikogruppen-risikosituationen/impfprinzipien-imid-gastro.pdf.download.pdf", "https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/empfehlungen-risikogruppen-risikosituationen/empfehlungen-onkologie.pdf.download.pdf/BU_20_22_Impfempfehlung_Onkologie_DE.pdf", "https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/empfehlungen-risikogruppen-risikosituationen/impfempfehlung-herpes-zoster.pdf.download.pdf/impfempfehlung-herpes-zoster-de.pdf", "https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/empfehlungen-spezifische-erreger-krankheiten/pneumokokken/empfehlung-verhinderung-invasive-pneumokokkenerkrankung-risikogruppen.pdf.download.pdf/bu-8-2014-pneumokokken-risikogruppen.pdf", "https://www.rheuma-net.ch/de/dok/sgr-dokumente/behandlung/therapie/weitere/72-impfempfehlungen-fuer-patienten-mit-entzuendlich-rheumatischen-erkrankungen/file?force-download=1", "https://www.rheumaliga.ch/blog/2020/infektionen-immunsuppression-impfungen", "https://www.pneumo.ch/de/home.html", "https://www.lungenliga.ch/de/startseite.html", "https://www.onkopedia.com/de/onkopedia/guidelines/impfungen-bei-tumorpatienten/@@guideline/html/index.html", "https://www.sgh-ssh.ch", "https://sggssg.ch", "https://www.swissneuro.ch/Home", "https://www.sginf.ch", "https://www.swissnoso.ch", "https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-i/gesundheitsversorgung-asyl/empfehlungen-impfungen-ausbruchsmanagement-asyl.pdf.download.pdf/empfehlungen-impfungen-ausbruchsmanagement-asyl-de.pdf", "https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/empfehlungen-risikogruppen-risikosituationen/empfehlungen-impfung-blut-stammzellen.pdf.download.pdf/bu-08-blutstammzellen.pdf", "https://www.bag.admin.ch/bag/de/home/das-bag/aktuell/news/masern-verursachen-zwei-todesfaelle.html", "https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/allgemeine-empfehlungen/schweizerischer-impfplan.pdf.download.pdf/schweizerischer-impfplan-de.pdf", "https://emh.ch/en/emh/rights-and-licences/", "#top", null, null, "tel:+410614678555", "#", "https://www.swisshealthweb.ch/de/newsfeed/", "https://www.swisshealthweb.ch/de/informationen-und-services/qualitaetssicherung/", "https://www.swisshealthweb.ch/de/informationen-und-services/publizistische-leitlinien/", "https://www.swisshealthweb.ch/de/informationen-und-services/copyright/", "https://www.swisshealthweb.ch/de/informationen-und-services/newsletter/", "https://www.swisshealthweb.ch/de/verlag/ueber-emh/", "https://www.swisshealthweb.ch/de/verlag/inserieren/", "https://www.swisshealthweb.ch/de/verlag/jobs/", "https://www.swisshealthweb.ch/de/partner/", "https://www.swisshealthweb.ch/de/verlag/hilfe-und-kontakt/", "https://www.swisshealthweb.ch/de/agb/", "https://www.swisshealthweb.ch/de/verlag/impressum/", "https://www.swisshealthweb.ch/de/verlag/datenschutz/", "https://www.swisshealthweb.ch/de/verlag/disclaimer/", "javascript:void()"]}